WO2021007524A3 - Clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies - Google Patents

Clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies Download PDF

Info

Publication number
WO2021007524A3
WO2021007524A3 PCT/US2020/041621 US2020041621W WO2021007524A3 WO 2021007524 A3 WO2021007524 A3 WO 2021007524A3 US 2020041621 W US2020041621 W US 2020041621W WO 2021007524 A3 WO2021007524 A3 WO 2021007524A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
tumor
infiltrating leukocytes
leukocytes
hematologic malignancies
Prior art date
Application number
PCT/US2020/041621
Other languages
French (fr)
Other versions
WO2021007524A2 (en
Inventor
Larry Norton
Ross LEVINE
Maria KLEPPE
Elizabeth COMEN
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of WO2021007524A2 publication Critical patent/WO2021007524A2/en
Publication of WO2021007524A3 publication Critical patent/WO2021007524A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to clonal hematopoiesis mutations in leukocytes infiltrating primary breast cancers as a precursor to secondary hematologic malignancies. Disclosed herein are results from genomic analysis of microdissected breast cancer tumor cells and tumor-infiltrating leukocytes from breast cancer patients who subsequently developed leukemia. In a subset of the patients, mutations present in the leukemia were detected in the tumor-infiltrating leukocytes of the breast cancer prior to treatment. Thus, in at least some patients, tumor-infiltrating leukocytes in the primary breast cancer may harbor the ancestor of the future leukemogenic clone.
PCT/US2020/041621 2019-07-10 2020-07-10 Clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies WO2021007524A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962872415P 2019-07-10 2019-07-10
US62/872,415 2019-07-10
US201962872969P 2019-07-11 2019-07-11
US62/872,969 2019-07-11

Publications (2)

Publication Number Publication Date
WO2021007524A2 WO2021007524A2 (en) 2021-01-14
WO2021007524A3 true WO2021007524A3 (en) 2021-04-08

Family

ID=74114829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/041621 WO2021007524A2 (en) 2019-07-10 2020-07-10 Clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies

Country Status (1)

Country Link
WO (1) WO2021007524A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102367A1 (en) * 2013-06-03 2016-04-14 The Trustees Of Columbia University In The City Of New York Recurrent mutations in epigenetic regulators, rhoa and fyn kinase in peripheral t-cell lymphomas
US20170363635A1 (en) * 2014-12-08 2017-12-21 Memorial Sloan Kettering Cancer Center Methods of Treating and Prognosing Nonhematopoietic Malignant Tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160102367A1 (en) * 2013-06-03 2016-04-14 The Trustees Of Columbia University In The City Of New York Recurrent mutations in epigenetic regulators, rhoa and fyn kinase in peripheral t-cell lymphomas
US20170363635A1 (en) * 2014-12-08 2017-12-21 Memorial Sloan Kettering Cancer Center Methods of Treating and Prognosing Nonhematopoietic Malignant Tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CRISTOFANILLI ET AL.: "Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-b: clinical activity and biological correlations", ANNALS OF ONCOLOGY, vol. 19, no. 10, October 2008 (2008-10-01), pages 1713 - 1719, XP055113837, DOI: 10.1093/annonc/mdn352 *
JU ET AL.: "Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer", ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY, vol. 46, no. suppl. 1, 30 January 2018 (2018-01-30), pages 616 - 628, XP055811562 *
LAAKMANN ET AL.: "Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer", BREAST CARE, vol. 12, no. 3, July 2017 (2017-07-01), pages 165 - 167, XP055811564 *
SEVCIKOVA ET AL.: "Therapy-Related Myeloid Neoplasms in Breast Cancer Patients: A Single- Institution Report of 150 Cases", BLOOD, vol. 124, no. 21, 2014, pages 1 - 6, XP055811565 *
SHEN ET AL.: "Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex", CELL, vol. 165, no. 2, 7 April 2016 (2016-04-07), pages 331 - 342, XP029496633, DOI: 10.1016/j.cell.2016.02.064 *

Also Published As

Publication number Publication date
WO2021007524A2 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
EP4338799A3 (en) Tumor infiltrating lymphocytes and methods of therapy
MX2020008882A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
JP2019517788A5 (en)
ZA202306801B (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
TW200616615A (en) Compounds and methods for the treatment of cancer
WO2019236633A3 (en) Cell-based vehicles for potentiation of viral therapy
CA3045495A1 (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
BR112022008215A2 (en) GENERATION OF PRIMARY AND EXPANDED HUMAN NK CELLS CD38 KNOCK-OUT
USD915062S1 (en) Three point chest harness
MX2021008605A (en) Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers.
EP4023233A3 (en) Optimized oncolytic viruses and uses thereof
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
MX2021010288A (en) Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof.
WO2021007524A3 (en) Clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies
MX2021014524A (en) Methods of treating urinary system cancers.
MX2021003262A (en) Treatment methods.
MX2022007779A (en) Treatment involving immune effector cells genetically modified to express antigen receptors.
WO2012044817A3 (en) Process for preparing delta-7,9(11) steroids from ganoderma lucidum and analogs thereof
MX2021003265A (en) Treatment methods.
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
Slotman et al. Surgery and postoperative radiotherapy and radiotherapy alone in T3-T4 cancers of the pyriform sinus: treatment results and patterns of failure
WO2022115565A3 (en) Chimeric receptors and methods of use thereof
MY197281A (en) Oral composite tablet comprising ezetimibe and rosuvastatin
Dornelas An overview of cancer for the mental health professional.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20837079

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 20837079

Country of ref document: EP

Kind code of ref document: A2